Research and Collaboration Arrangements - CFF - Additional Information (Details) - CFF Agreement - Cystic Fibrosis Foundation |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |
|---|---|---|---|---|---|
|
Aug. 31, 2023
USD ($)
|
Sep. 30, 2016
USD ($)
Installment
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Collaborative arrangement total amount of award | $ 6,300,000 | $ 3,500,000 | |||
| Collaborative arrangement achieved cumulative milestones | $ 1,800,000 | $ 1,800,000 | |||
| Expected payments multiples to equal actual award received | 6 | ||||
| Number of installments to pay actual award | Installment | 3 | ||||
| Actual award payment period upon first commercial sale of product | 4 years | ||||
| Continuous period where the Company ceases to develop or commercialize any product | 180 days | ||||
| Collaborative arrangements special term | If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company’s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license. | ||||
| Revenue recognized | $ 100,000 | 200,000 | |||
| Deferred revenue | 900,000 | 900,000 | 1,100,000 | ||
| Accounts receivable | 0 | 0 | 0 | ||
| Aggregate amount of transaction price allocated to remaining performance obligation | $ 900,000 | $ 900,000 | $ 1,100,000 | ||
| Maximum | |||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Future sales-based milestone payments multiples | 3 | ||||
| Royalties multiples on actual award received | 6 | ||||